MONTREAL, March 19 /CNW Telbec/ - Aegera Therapeutics Inc. is extremely
pleased to announce the appointment of Mr. James M. Rae as Chairman of the
Board and Ms. Trudie Resch as Board Director.
"Jim's vast business and development experience will be instrumental in
guiding and helping Aegera meet its clinical and business objectives in the
field of cancer and pain-related therapeutics", stated Dr. Michael Berendt,
President and CEO of Aegera Therapeutics. "Furthermore, Jim's knowledge and
network will be synergistic to that of our current Board members and I am
looking forward to working closely with him to accelerate our company's growth
Mr. Rae has more than 40 years experience in the pharmaceutical industry.
He has held multiple executive positions ranging from Marketing Manager to
President and CEO at Searle Canada (1969-1988) and Cangene Corporation (1988 -
1996). Since 1996, as President of Remedis Consulting, he has provided
strategic and hands-on M&A consulting for numerous biotechnology companies
including Cytochroma, Resolution Pharma and Vaxis Therapeutics. Mr. Rae also
serves as Chairman of Queen's Scientific Breakthrough Fund, as Executive
Director of Elastin Specialties Inc., and holds Board seats on three other
Canadian biotechnology companies.
Also joining Aegera's Board of Directors is Ms. Trudie Resch, a
long-standing biotechnology investment professional. Ms. Resch, currently
responsible for managing the life sciences investment team at Desjardins
Venture Capital, has a long and successful track record in life sciences
investments across North America. Prior to her position with Desjardins, Ms.
Resch worked as a business consultant to the industry where she was involved
in a number of successful M&A transactions and prior to that, held the
position of Vice-President and Partner with CDP Capital Technology Ventures.
Commenting on Ms. Resch's appointment, Dr. Michael Berendt said that "Trudie
brings to Aegera's Board of Directors significant business and financial
experience that will add to and complement the expertise and networks of our
other board members."
Dr. Berendt concluded that "With the addition of Jim and Trudie, to our
Board of Directors, I am very confident that we have a Board with the
experience, networks and skill sets to help accelerate the growth and
development of Aegera as we continue to aggressively manage the clinical
advancement of our apoptosis-focused programs."
Aegera's Board consists of the following members:
- Mr. James M. Rae, President, Remedis Consulting
- Dr. Michael J. Berendt, President & CEO, Aegera Therapeutics Inc.
- Dr. Luc Marengère, Managing General Partner, VenGrowth Equity Partners
- Dr. Louisa Petropoulos, Principal, Multiple Capital
- Mr. Joseph Regan, Vice-President, GrowthWorks
- Ms. Trudie Resch, Consultant, Desjardins Venture Capital
- Mr. Lennie Ryer, Vice-President & CFO, ConjuChem Biotechnologies Inc.
About Aegera Therapeutics Inc.
Aegera Therapeutics Inc. ("Aegera") is a clinical stage company focused
on developing drugs to control apoptosis to address major unmet medical needs.
Our lead programs are in development to induce apoptosis to kill cancer cells
and to prevent apoptosis to save injured neuronal cells. AEG35156, which
targets the key anti-apoptic protein XIAP, is currently in multiple human
clinical trials for the treatment of solid tumors and leukemia. Aegera is also
developing potent small molecule IAP inhibitors for the treatment of multiple
cancers and developing novel oral small molecules for the treatment of
neuropathic pain and neuropathies induced by diabetes or chemotherapy. For
more information: www.aegera.com
For further information:
For further information: Aegera Therapeutics Inc., Donald Olds, Chief
Operating Officer & CFO, (514) 288-5532, *295, email@example.com